MedPath

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

Phase 3
Completed
Conditions
Chronic Kidney Disease (CKD)
Interventions
Other: Standard of Care Arm
Biological: Epoetin Hospira Arm
Registration Number
NCT02504294
Lead Sponsor
Pfizer
Brief Summary

A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.

Detailed Description

Primary Objective: To evaluate switching from Epogen to Epoetin Hospira for maintenance of hemoglobin levels in anemic chronic kidney disease (CKD) subjects on hemodialysis using a specified algorithm for the dosing of erythropoietin stimulating agents (ESA).

Secondary Objective: To evaluate switching from Epogen to Epoetin Hospira on the dosing of ESA in anemic CKD subjects on hemodialysis using a specified algorithm for the dosing of ESA.

Exploratory Objectives: To generate hypotheses regarding maintenance of hemoglobin levels, dosing of ESA, intravenous (IV) iron dosing requirements, transferrin saturation (TSAT) levels and ferritin levels associated with the switch from Epogen to Epoetin Hospira in anemic CKD subjects on hemodialysis using specified algorithms for the dosing of ESA and for the dosing of IV iron, that are standard of care.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
432
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Epoetin HospiraIV IronEpoetin Hospira Arm
Standard of CareStandard of Care ArmStandard of care arm
Standard of CareIV IronStandard of care arm
Epoetin HospiraEpoetin Hospira ArmEpoetin Hospira Arm
Primary Outcome Measures
NameTimeMethod
Percentage of Time When Participants Had Hemoglobin Levels Between 9 to 11 Gram Per Deciliter (g/dL)Week 17 up to Week 24
Secondary Outcome Measures
NameTimeMethod
Change From Baseline in Weekly Mean Study Medication Dose Over Final 8 Weeks of Study TreatmentBaseline (8 Weeks prior to randomization), Week 17 up to Week 24

Trial Locations

Locations (36)

Briggs Avenue Dialysis Center

🇺🇸

Durham, North Carolina, United States

California Institute of Renal Research at Fresenius Medical Care Kearny Mesa

🇺🇸

San Diego, California, United States

Nephrology Associates, PC

🇺🇸

Nashville, Tennessee, United States

North Gulfport

🇺🇸

Gulfport, Mississippi, United States

Frenova Renal Research

🇺🇸

Nampa, Idaho, United States

Metrolina Nephrology Associates, PA

🇺🇸

Charlotte, North Carolina, United States

Fresenius Medical Care North America - Liberty Dialysis

🇺🇸

Nampa, Idaho, United States

Fresenius Medical Care Paradise Valley

🇺🇸

San Diego, California, United States

Fresenius Medical Care, Biloxi Dialysis Unit

🇺🇸

Biloxi, Mississippi, United States

Fresenius Medical Care-Oshtemo

🇺🇸

Kalamazoo, Michigan, United States

Paragon Health PC DBA Nephrology Center

🇺🇸

Kalamazoo, Michigan, United States

Fresenius Medical Care-Franklin

🇺🇸

Franklin, Tennessee, United States

FMC Charlotte

🇺🇸

Charlotte, North Carolina, United States

FMC Matthews

🇺🇸

Matthews, North Carolina, United States

Fresenius Medical Care Carolina

🇵🇷

Carolina, Puerto Rico

Gamma Medical Research Inc

🇺🇸

McAllen, Texas, United States

Fresenius Medical Care San Juan

🇵🇷

San Juan, Puerto Rico

Mission Bend Dialysis (FMC#3971)

🇺🇸

Houston, Texas, United States

Rosenberg Dialysis (FMC#1197)

🇺🇸

Rosenberg, Texas, United States

California Institute of Renal Research

🇺🇸

Chula Vista, California, United States

California Institute of Renal Research at Fresenius Medical Care

🇺🇸

Poway, California, United States

Fresenius Medical Care Rancho

🇺🇸

Rancho Bernardo, California, United States

Fresenius Medical Care

🇵🇷

Humacao, Puerto Rico

Genesis Clinical Research, LLC

🇺🇸

Tampa, Florida, United States

Fresenius Medical Care-Kalamazoo East

🇺🇸

Kalamazoo, Michigan, United States

South Mississippi Kidney Center

🇺🇸

Gulfport, Mississippi, United States

Durham Nephrology Associates

🇺🇸

Durham, North Carolina, United States

Delaware Valley Nephrology and Hypertension Associates, PC

🇺🇸

Philadelphia, Pennsylvania, United States

Fresenius Medical Care- Lansdale Dialysis

🇺🇸

Lansdale, Pennsylvania, United States

Knoxville Kidney Center, PLLC

🇺🇸

Knoxville, Tennessee, United States

Southwest Houston Research, Ltd.

🇺🇸

Houston, Texas, United States

Fresenius Medical Care - Austin North 4478

🇺🇸

Austin, Texas, United States

Fresenius Medical Care Weslaco

🇺🇸

Weslaco, Texas, United States

Fresenius Crossville Dialysis Unit

🇺🇸

Crossville, Tennessee, United States

Fresenius Dialysis West

🇺🇸

Knoxville, Tennessee, United States

Research Management Inc

🇺🇸

Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath